TICKERNERD
Menu
LUCDLUCDHealthcare · Medical Devices

LUCD Stock Forecast: Lucid Diagnostics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$0.65
+4.18% on the day

The 5 Wall Street analysts covering Lucid Diagnostics, Inc. hold a median 12-month price target of $3 — +361.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$119.1M
Ticker Nerd rank
35 / 100
Median analyst target
$3.00
Analysts covering
5
Revenue$1.5M+26.7% y/y
Operating income−$12.8M
Net income−$11.7M
Free cash flow−$11.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.4%
1M
−27.5%
YTD
−40.4%
1Y
−46.7%
From 52W high
−55.8%
From 52W low
+9.6%
$0.59
$1.47
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LUCD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lucid Diagnostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
35 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
85
Growth
76
Size
72
Issuance
55
Revisions
37
Volatility
36
Momentum
28
Quality
18
Value
6

Accruals (85): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (6): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LUCD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LUCD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26LUCDHigh $9.50Median $3.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $2.00Median $3.00High $9.50

The green dot is the last close — the median target sits +361.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Aug 2026Ascendiant CapitalMaintainsBuy$9.25 → $9.50
17 Aug 2026BTIGReiteratesBuy—
17 Aug 2026BTIGReiteratesBuy$2.50
8 June 2026Ascendiant CapitalMaintainsBuy—
8 June 2026Ascendiant CapitalMaintainsBuy$9.00 → $9.25
15 May 2026BTIGReiteratesBuy—
15 May 2026Maxim GroupMaintainsBuy—
9 Apr 2026Ascendiant CapitalMaintainsBuy—
30 Mar 2026BTIGReiteratesBuy—
26 Mar 2026NeedhamReiteratesBuy—
10 Dec 2025Ascendiant CapitalMaintainsBuy—
13 Nov 2025NeedhamReiteratesBuy—
6 Oct 2025Ascendiant CapitalMaintainsBuy—
10 Sept 2025BTIGReiteratesBuy—
5 Sept 2025BTIGMaintainsBuy—
13 Aug 2025NeedhamReiteratesBuy—
16 July 2025NeedhamReiteratesBuy—
6 June 2025Ascendiant CapitalMaintainsBuy—
15 May 2025Cantor FitzgeraldReiteratesOverweight—
14 May 2025NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LUCD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

LUCD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Lucid Diagnostics, Inc. returned −46.7% against +16.2% for the S&P 500, dividends included.

LUCD vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26LUCDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LUCD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Lucid Diagnostics, Inc. (LUCD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.5×

Cheaper than 84% of US stocks

Price / sales
22.0×

Cheaper than 8% of US stocks

Price / book
11.0×

Cheaper than 8% of US stocks

EV / EBITDA
−2.2×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
26.7%

Higher than 76% of US stocks

Earnings growth (YoY)
26.7%

Higher than 64% of US stocks

Gross margin
2.0%

Higher than 5% of US stocks

Operating margin
−868.5%

Higher than 6% of US stocks

Net margin
−41.7%

Higher than 11% of US stocks

Returns & dividend
Return on equity
−556.3%

Higher than 3% of US stocks

Return on assets
−81.6%

Higher than 4% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Lucid Diagnostics, Inc. (LUCD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Lucid Diagnostics, Inc. has a market value of $119.1M and an enterprise value of $109.5M.

  • Revenue in the twelve months to 30 June 2026: $5.4M. The latest quarter grew 26.7% year on year.

  • Net income over the same four quarters: −$52.3M, a −959.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.45.

  • Free cash flow in the twelve months to 30 June 2026: −$47.2M.

  • Shares outstanding: 190.8M.

  • Trailing P/E: −1.5×; forward P/E: −3.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Lucid Diagnostics, Inc. employs 82 people — $66K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

LUCD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
LUCDLucid Diagnostics, Inc.$119.1M
35
OWLTOwlet, Inc.$135.1M
39
QTRXQuanterix Corp.$151.2M
28
MXCTMaxCyte, Inc.$109.3M
75
INGNInogen, Inc.$161.8M
81
STIMNeuronetics, Inc.$163.1M
66
HYPRHyperfine, Inc.$99.7M
44

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lucid Diagnostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LUCD news & analysis

Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

PRNewsWire · 22 Sept 2026positive

Lucid Diagnostics announced advances in payment, billing, and coding pathways for its EsoGuard and EsoCheck products, following three public meetings. These include a Medicare Advisory Panel recommendation to maintain EsoGuard's gapfill payment basis, AMA CPT approval of a new Category III code for EsoCheck procedures, and a favorable response to a proposed new ICD-10-CM diagnosis code for positive EsoGuard results.

Why it matters — These coding, billing, and payment advances could strengthen reimbursement coverage and market accessibility for Lucid's EsoGuard and EsoCheck products.

Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth

MarketBeat · 15 Aug 2026neutral

Lucid Diagnostics is positioning its EsoGuard test as a non-invasive tool for identifying Barrett's Esophagus while awaiting a Medicare coverage decision and expanding relationships with commercial payers, the Department of Veterans Affairs, and health systems.

Why it matters — The Medicare coverage decision and expanding payer and health system relationships could significantly determine EsoGuard's adoption and revenue potential.

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

PRNewsWire · 14 Aug 2026positive

PAVmed provided a business update and reported second quarter 2026 financial results for its subsidiaries, including Lucid Diagnostics. As part of the update, Lucid Diagnostics secured its first laboratory benefit manager coverage policy for EsoGuard.

Why it matters — This marks a coverage milestone for Lucid's EsoGuard product, which could expand patient access to the test.

Lucid Diagnostics Inc. (LUCD) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

Seeking Alpha published the transcript of Lucid Diagnostics Inc.'s (LUCD) Q2 2026 earnings call. The item consists solely of the call transcript, providing a record of management's discussion of the company's second-quarter 2026 results.

Why it matters — LUCD watchers can review the full earnings call transcript directly to understand management's own commentary on the company's recent performance, without third-party interpretation.

Lucid Diagnostics Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026neutral

Lucid Diagnostics reported second-quarter revenue of $1.5 million from 2,770 EsoGuard tests, maintaining its target of roughly 2,500 to 3,000 quarterly tests while awaiting a Medicare draft local coverage determination.

Why it matters — A LUCD watcher would care because the company's test volume and revenue performance are tied to the pending Medicare coverage decision that could affect future demand for EsoGuard.

FAQ

Frequently asked questions about LUCD stock

What is the LUCD stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Lucid Diagnostics, Inc. have a median 12-month price target of $3, with estimates ranging from $2 to $9.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LUCD stock a buy right now?

Of the 5 analysts covering Lucid Diagnostics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lucid Diagnostics, Inc. 35 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LUCD?

As at 8 Oct 2026, Lucid Diagnostics, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (85 of 100).

Will LUCD stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +361.5% from the last close, and Ticker Nerd's factor model ranks Lucid Diagnostics, Inc. 35 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LUCD stock forecast for 2030?

No analyst covering Lucid Diagnostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LUCD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $9.5 over the next 12 months.

How has LUCD stock performed over the past year?

Lucid Diagnostics, Inc. returned -46.7% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lucid Diagnostics, Inc. do?

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on the early detection of esophageal precancer and cancer in patients with gastroesophageal reflux disease, or GERD.

What is the latest news on LUCD?

The most recent item we track (PRNewsWire, 22 Sept 2026): "Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways". Lucid Diagnostics announced advances in payment, billing, and coding pathways for its EsoGuard and EsoCheck products, following three public meetings. These include a Medicare Advisory Panel recommendation to maintain EsoGuard's gapfill payment basis, AMA CPT approval of a new Category III code for EsoCheck procedures, and a favorable response to a proposed new ICD-10-CM diagnosis code for positive EsoGuard results.

Company

About Lucid Diagnostics, Inc.

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on the early detection of esophageal precancer and cancer in patients with gastroesophageal reflux disease, or GERD. Its core offering centers on the EsoGuard Esophageal DNA Test, which is performed using samples collected with the EsoCheck Esophageal Cell Collection Device to help identify at-risk patients before disease progresses. The company’s products are designed for use in clinical settings and support physicians in screening patients who may benefit from further evaluation. Lucid Diagnostics serves the healthcare market by addressing an important unmet need in cancer prevention and risk assessment, particularly for a condition linked to highly lethal esophageal adenocarcinoma. The company is headquartered in New York, New York, and operates as a subsidiary of PAVmed Inc.

CEO Dr. Lishan Aklog M.D. · 82 employees · United States · https://www.luciddx.com